SCHEMBL21995625

SCHEMBL21995625

Cc1cccc(Oc2ncc(-c3ccc(N)nc3)cn2)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.68
KMT2A Q03164 2/20 0.68
HTT P42858 2/20 0.68
CDK8 P49336 3/20 0.48
ALDH1A1 P00352 3/20 0.46
MAP4K4 O95819 2/20 0.46
NPSR1 Q6W5P4 2/20 0.44
GAA P10253 2/20 0.44
LTA4H P09960 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
LYN P07948 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.40
LMNA P02545 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
MAPT P10636 1/20 0.40
NOS3 P29474 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24156273 0.85 MEN1 (0.72) MEN1KMT2AHTTALDH1A1NPSR1
SCHEMBL24156289 0.84 KMT2A (0.48) MEN1KMT2AHTTCDK8MAP4K4
SCHEMBL24155490 0.82 MEN1 (0.67) MEN1KMT2AHTTALDH1A1MAP4K4
SCHEMBL21995538 0.82 MEN1 (0.63) MEN1KMT2AHTTALDH1A1MAP4K4
SCHEMBL24155830 0.80 MEN1 (0.64) MEN1KMT2AHTTALDH1A1NPSR1
SCHEMBL21399637 0.80 HTT (0.67) MEN1KMT2AHTTALDH1A1MAP4K4
SCHEMBL24155633 0.80 PIK3CD (0.46) MEN1KMT2AHTTALDH1A1MAP4K4
SCHEMBL24155496 0.80 BTK (0.46) MEN1KMT2AHTTCDK8MAP4K4
SCHEMBL12349144 0.78 MAP4K4 (0.68) MEN1KMT2AALDH1A1MAP4K4NPC1
SCHEMBL24155608 0.77 DYRK1A (0.50) MEN1KMT2AHTTALDH1A1MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304558-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-10-02 US disclosed
US-12391674-B2 Heterocyclic compounds for the treatment of epilepsy OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-08-19 US disclosed
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-12-30 US disclosed
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-12-30 US disclosed
EP-3887358-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY Otsuka Pharmaceutical Co., Ltd. (JP) 2021-10-06 EP disclosed
CN-113166076-A Heterocyclic compounds for the treatment of epilepsy 大塚制药株式会社 2021-07-23 CN disclosed
WO-2020111263-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12391674-B2 Heterocyclic compounds for the treatment of epilepsy SLC6A11, SCN1A, SCN1B MEN1 450/4885KMT2A 279/4885HTT 2045/4885
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY SLC6A11, SCN1A, SCN1B MEN1 450/4885KMT2A 279/4885HTT 2045/4885
US-20250304558-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY SLC6A11, SCN1A, KCNH1 MEN1 402/4885KMT2A 379/4885HTT 2067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.